Holdings of Zentalis Pharmaceuticals Inc. (ZNTL) are aligned with the stars

Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) stock fell -1.90% on Thursday to $23.79 against a previous-day closing price of $24.25. With 1.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.57 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $24.27 whereas the lowest price it dropped to was $23.12. The 52-week range on ZNTL shows that it touched its highest point at $31.46 and its lowest point at $15.55 during that stretch. It currently has a 1-year price target of $49.60. Beta for the stock currently stands at 1.79.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZNTL was down-trending over the past week, with a drop of -4.99%, but this was down by -13.93% over a month. Three-month performance dropped to -3.41% while six-month performance rose 30.21%. The stock lost -10.06% in the past year, while it has gained 18.12% so far this year. A look at the trailing 12-month EPS for ZNTL yields -4.82 with Next year EPS estimates of -4.46. For the next quarter, that number is -0.94. This implies an EPS growth rate of -20.50% for this year and 7.50% for next year.

Float and Shares Shorts:

At present, 70.61 million ZNTL shares are outstanding with a float of 68.71 million shares on hand for trading. On Aug 14, 2023, short shares totaled 12.39 million, which was 17.54% higher than short shares on Jul 13, 2023. In addition to Dr. Kimberly Lynn Blackwell M.D. as the firm’s CEO & Director, Mr. Cameron S. Gallagher M.B.A. serves as its Co-Founder, Pres & Director.

Institutional Ownership:

Through their ownership of 102.09% of ZNTL’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 61.95% of ZNTL, in contrast to 49.61% held by mutual funds. Shares owned by individuals account for 13.94%. As the largest shareholder in ZNTL with 19.80% of the stake, Matrix Capital Management Co. LP holds 13,959,973 shares worth 13,959,973. A second-largest stockholder of ZNTL, Fidelity Management & Research Co, holds 10,119,378 shares, controlling over 14.35% of the firm’s shares. Eventide Asset Management LLC is the third largest shareholder in ZNTL, holding 6,877,803 shares or 9.75% stake. With a 5.67% stake in ZNTL, the Eventide Healthcare & Life Scienc is the largest stakeholder. A total of 4,000,000 shares are owned by the mutual fund manager. The American Funds Small Cap World Fu, which owns about 5.41% of ZNTL stock, is the second-largest Mutual Fund holder. It holds 3,810,758 shares valued at 101.79 million. Catalyst Eventide Gilead Fund holds 4.08% of the stake in ZNTL, owning 2,877,034 shares worth 76.85 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Jun 29, 2023, ZNTL reported revenue of $0.00 and operating income of -$63.46M. The EBITDA in the recently reported quarter was -$63.54M and diluted EPS was -$1.34.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZNTL since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZNTL analysts setting a high price target of $55.00 and a low target of $37.00, the average target price over the next 12 months is $46.75. Based on these targets, ZNTL could surge 131.19% to reach the target high and rise by 55.53% to reach the target low. Reaching the average price target will result in a growth of 96.51% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded ZNTL stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 4,811,787 shares were bought while 0 shares were sold. The number of buy transactions has increased to 15 while that of sell transactions has risen to 29 over the past year. The total number of shares bought during that period was 5,760,318 while 292,633 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *